B
Beicheng Sun
Researcher at Nanjing University
Publications - 192
Citations - 7794
Beicheng Sun is an academic researcher from Nanjing University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 40, co-authored 163 publications receiving 5555 citations. Previous affiliations of Beicheng Sun include University of Texas Health Science Center at San Antonio & Nanjing Medical University.
Papers
More filters
Journal ArticleDOI
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance
Qiang Wang,Chen Chen,Qingqing Ding,Yan Zhao,Zhangding Wang,Junjie Chen,Zerun Jiang,Yan Zhang,Guifang Xu,Jingjing Zhang,Jianwei Zhou,Beicheng Sun,Xiaoping Zou,Shouyu Wang +13 more
TL;DR: Elevated METTL3 expression promotes tumour angiogenesis and glycolysis in GC, indicating that METTL 3 expression is a potential prognostic biomarker and therapeutic target for human GC.
Journal ArticleDOI
Obesity, Inflammation, and Liver Cancer
Beicheng Sun,Michael Karin +1 more
TL;DR: Recent advances in elucidation of cellular and molecular alterations and signaling pathways associated with obesity and liver inflammation and their contribution to hepatocarcinogenesis are reviewed and discussed.
Journal ArticleDOI
Obesity and Cancer: The Oil that Feeds the Flame
TL;DR: Recent advances in understanding how obesity increases cancer risk are discussed and a unifying hypothesis according to which the major tumor-promoting mechanism triggered by hypernutrition is the indolent inflammation that takes place at particular organ sites, including liver, pancreas, and gastrointestinal tract is proposed.
Journal ArticleDOI
NF-κB signaling, liver disease and hepatoprotective agents
Beicheng Sun,Michael Karin +1 more
TL;DR: The NF-κB signaling pathway has particular relevance to several liver diseases including hepatitis, viral hepatitis induced by HBV and HCV, liver fibrosis and cirrhosis and hepatocellular carcinoma, and is a potential target for development of hepatoprotective agents.
Journal ArticleDOI
Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
TL;DR: Excessive IL‐22 can be found in the HCC microenvironment, leading to tumor growth, inhibition of apoptosis, and promotion of metastasis due to STAT3 activation.